CIGLIANO, Antonio
 Distribuzione geografica
Continente #
NA - Nord America 5.248
AS - Asia 3.012
SA - Sud America 1.746
EU - Europa 1.375
AF - Africa 115
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 7
Totale 11.511
Nazione #
US - Stati Uniti d'America 5.110
BR - Brasile 1.520
SG - Singapore 1.258
CN - Cina 719
UA - Ucraina 425
VN - Vietnam 312
HK - Hong Kong 282
DE - Germania 218
IT - Italia 194
FR - Francia 135
AR - Argentina 82
FI - Finlandia 81
GB - Regno Unito 75
SE - Svezia 70
IN - India 57
BD - Bangladesh 54
CA - Canada 54
IQ - Iraq 54
EC - Ecuador 43
ID - Indonesia 40
MX - Messico 39
TR - Turchia 38
RU - Federazione Russa 32
ZA - Sudafrica 28
MA - Marocco 26
UZ - Uzbekistan 26
PK - Pakistan 25
CZ - Repubblica Ceca 23
VE - Venezuela 23
CO - Colombia 21
BE - Belgio 20
JP - Giappone 20
NL - Olanda 18
PY - Paraguay 18
KR - Corea 17
PL - Polonia 17
AT - Austria 16
PE - Perù 14
CL - Cile 13
DZ - Algeria 13
KE - Kenya 13
ES - Italia 11
EG - Egitto 9
AE - Emirati Arabi Uniti 8
AU - Australia 8
AZ - Azerbaigian 8
DO - Repubblica Dominicana 8
IL - Israele 8
JO - Giordania 8
TN - Tunisia 8
NP - Nepal 7
SA - Arabia Saudita 7
UY - Uruguay 7
CR - Costa Rica 6
EU - Europa 6
JM - Giamaica 6
KZ - Kazakistan 6
LT - Lituania 6
OM - Oman 6
PA - Panama 6
PH - Filippine 6
TT - Trinidad e Tobago 6
BG - Bulgaria 5
IR - Iran 5
PS - Palestinian Territory 5
AM - Armenia 4
BO - Bolivia 4
BY - Bielorussia 4
GR - Grecia 4
HN - Honduras 4
KG - Kirghizistan 4
LB - Libano 4
MY - Malesia 4
NI - Nicaragua 4
RO - Romania 4
RS - Serbia 4
SN - Senegal 4
AL - Albania 3
BH - Bahrain 3
BN - Brunei Darussalam 3
CI - Costa d'Avorio 3
GE - Georgia 3
IE - Irlanda 3
LK - Sri Lanka 3
NG - Nigeria 3
SY - Repubblica araba siriana 3
BA - Bosnia-Erzegovina 2
MD - Moldavia 2
MU - Mauritius 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BB - Barbados 1
BS - Bahamas 1
BW - Botswana 1
CG - Congo 1
CY - Cipro 1
DK - Danimarca 1
ET - Etiopia 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 11.501
Città #
Dallas 1.825
Singapore 692
Chandler 645
San Jose 361
Hong Kong 279
Ashburn 247
Jacksonville 226
Beijing 197
Princeton 184
New York 123
São Paulo 114
Nanjing 102
Ho Chi Minh City 100
Lauterbourg 95
Sassari 88
Ann Arbor 79
Hanoi 69
Wilmington 64
Los Angeles 61
Rio de Janeiro 56
Santa Clara 55
Shanghai 48
Belo Horizonte 41
Dearborn 41
Boardman 40
Nanchang 36
Council Bluffs 30
Munich 30
Helsinki 27
Baghdad 26
Curitiba 25
Mountain View 25
Orem 25
Tashkent 25
The Dalles 24
Changsha 22
Shenyang 22
Woodbridge 22
Brasília 21
Houston 21
Tianjin 21
Columbus 20
San Francisco 20
Toronto 20
Brussels 19
Buffalo 19
Denver 19
Atlanta 18
Brno 18
Campinas 18
Da Nang 18
Porto Alegre 18
Tokyo 18
Chennai 17
Guayaquil 17
Haiphong 17
Montreal 16
Ribeirão Preto 16
Seoul 16
Frankfurt am Main 15
Hebei 15
Andover 14
Jiaxing 14
Johannesburg 14
London 14
Quito 14
Salvador 14
Warsaw 14
Zhengzhou 14
Guarulhos 13
Nairobi 13
Norwalk 13
Fortaleza 12
Goiânia 12
Nuremberg 12
Rome 12
Santo André 12
Betim 11
Boston 11
Brooklyn 11
Dhaka 11
Jinan 11
Mexico City 11
Osasco 11
Juiz de Fora 10
Kunming 10
Manaus 10
Ningbo 10
Poplar 10
Recife 10
Stockholm 10
Asunción 9
Blumenau 9
Campo Grande 9
Caxias do Sul 9
Guangzhou 9
Joinville 9
Lima 9
São Gonçalo 9
Algiers 8
Totale 7.026
Nome #
A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis 346
Design, synthesis and antileukemia evaluation of Imatinib-like compounds as BCR-ABL1 protein kinase inhibitors 250
Design, synthesis and antileukemia evaluation of Imatinib-like compounds as BCR-ABL1 protein kinase inhibitors 242
New Imatinib-like compounds as Bcr-Abl1 protein kinase inhibitors: design, synthesis and biological evaluation 208
Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans 193
A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. IF 2009: 4.522 JCR: Q1 192
Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells 187
Activation of β-Catenin and Yap1 in Human Hepatoblastoma and Induction of Hepatocarcinogenesis in Mice. 183
Apolipoprotein Profiles in Atherosclerotic Disease 179
Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans 177
4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras protooncogenes 174
Apolipoprotein profiles in atherosclerotic disease 171
Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma 170
Aortic and pulmonary bioprosthetic heart valves: an insight on glycosaminoglycan distribution and fine structure in decellularized porcine scaffolds for tissue engineering purposes 165
Association between human plasma chondroitin sulphate isomers and carotid atherosclerotic plaque 161
Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver 160
Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis 158
Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans 154
Apolipoprotein Profiles in Atherosclerotic Disease 153
MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting MAT2A and MAT2B genes 152
Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice 149
Apolipoprotein profiles in atherosclerotic disease 143
Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans 142
Combined CDK4/6 and pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma 142
The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models 141
Evaluation of human serum albumin sulfhydryl groups oxidation in plasma and atherosclerotic plaque extracts 136
Evaluation of plasma glycosaminoglycans levels and structure in patients undergoing carotid endarterectomy 134
Evaluation of human serum albumin sulfhydryl groups oxidation in plasma and atherosclerotic plaque extracts 133
Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma 132
Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines in vitro and AKT-driven hepatocarcinogenesis in mice 132
Central role of mTORC1 downstream of YAP/TAZ in hepatoblastoma development 132
CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype 129
Differential distribution of structural components and hydration in aortic and pulmonary heart valve conduits: Impact of detergent-based cell removal. IF 2010: 4.824 JCR: Q1 129
Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma 127
Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice 127
Modification of the base excision repair enzyme MBD4 by the small ubiquitin-like molecule SUMO1 126
SNAI1 promotes the cholangiocellular phenotype, but not epithelial-mesenchymal transition, in a murine hepatocellular carcinoma model 123
The mTORC2-Akt1 Cascade Is Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans 123
Evaluation of plasma glycosaminoglycans levels and structure in patients undergoingcarotid endarterectomy 121
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma 118
Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade 113
Loss of Fbxw7 synergizes with activated AKT signaling to promote c-Myc dependent cholangiocarcinogenesis 106
HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma 105
Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma 105
PI3K/AKT/mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men. 105
Corrigendum to ‘TAZ is indispensable for c-MYC-induced hepatocarcinogenesis’ [J Hepatol (2022) 123–134] (Journal of Hepatology (2022) 76(1) (123–134), (S016882782102016X), (10.1016/j.jhep.2021.08.021)) 105
Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis 103
Pivotal role of fatty acid synthase in c-myc driven hepatocarcinogenesis 102
Structural analisys of plasma glycosaminoglycans in patients with atheromatous lesions 101
Loss of pten synergizes with c-met to promote hepatocellular carcinoma development via mTORC2 pathway 98
New Imatinib-like compounds as Bcr-Abl1 protein kinase inhibitors: design, synthesis and antileukemia evaluation 97
Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways. 96
The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease 95
Structural analysis of glycosaminoglycans from fresh and decellularized porcine aortic and pulmonary valves 95
Erratum: Frizzled-10 extracellular vesicles plasma concentration is associated with tumoral progression in patients with colorectal and gastric cancer (Journal of Oncology (2019) 2019 (2715968) DOI: 10.1155/2019/2715968) 94
Glycosaminoglycan content and distribution in human normal and varicose veins 93
PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells 93
New Capillary Zone Electrophoresis (CZE) method for glycosaminoglycan analysis 93
The Hippo Effector Transcriptional Coactivator with PDZ-Binding Motif Cooperates with Oncogenic β-Catenin to Induce Hepatoblastoma Development in Mice and Humans 92
Structural analysis of glycosaminoglycans from fresh and decellularized porcine aortic and pulmonary valves 92
Plasma levels of C-reactive protein, leptin and glycosaminoglycans during spontaneous menstrual cycle: differences between ovulatory and anovulatory cycles 90
TEA Domain Transcription Factor 4 Is the Major Mediator of Yes-Associated Protein Oncogenic Activity in Mouse and Human Hepatoblastoma 90
Nuclear localization dictates hepatocarcinogenesis suppression by glycine N-methyltransferase 89
Molecular and metabolic changes in human liver clear cell foci resemble the alterations occurring in rat hepatocarcinogenesis. 89
SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice 89
Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. 89
Glycosaminoglycan diversity in marine sponge extracellular matrix 88
Signaling and molecular networks related to development and inflammation involved in CCA initiation and progression 87
Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model 86
Hepatocellular glycogenotic foci after combined intraportal pancreatic islet transplantation and knockout of the carbohydrate responsive element binding protein in diabetic mice 85
Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges 84
GLYCOSAMINOGLYCAN DIVERSITY IN MARINE SPONGE EXTRACELLULAR MATRIX 83
Structural analysis of glycosaminoglycans from fresh and decellularized porcine aortic and pulmonary valves 83
Role of the Notch signaling in cholangiocarcinoma 82
Focal adhesion kinase activation limits efficacy of Dasatinib in c-Myc driven hepatocellular carcinoma 81
Frizzled-10 Extracellular Vesicles Plasma Concentration Is Associated with Tumoral Progression in Patients with Colorectal and Gastric Cancer 81
Proteomic study of differential protein expression in stable and unstable human atherosclerotic plaque 77
Glycosaminoglycans and fabry’s disease 77
Fine structure of glycosaminoglycans from fresh and decellularized porcine cardiac valves and pericardium 77
Fatty Acid Synthase Promotes Hepatocellular Carcinoma Growth via S-Phase Kinase-Associated Protein 2/p27KIP1 Regulation 76
Functional role of SGK3 in PI3K/Pten driven liver tumor development 76
Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair 76
Human serum albumin Cys34 oxidative modifications after infiltration in the carotid atherosclerotic plaque 75
Ultrasensitive Capillary Zone Electrophoresis (CZE) for glycosaminoglycan analisys in normal human plasma 75
Molecular and metabolic changes in human clear cell liver foci 74
Evaluation of human serum albumin sulfhydryl groups oxidation in plasma and atherosclerotic plaque extracts 73
Structural analysis of glycosaminoglycans from fresh porcine aortic valves 71
Transcriptomic and Proteomic Analysis of Clear Cell Foci (CCF) in the Human Non-Cirrhotic Liver Identifies Several Differentially Expressed Genes and Proteins with Functions in Cancer Cell Biology and Glycogen Metabolism 71
Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans 71
TGF-β as Multifaceted Orchestrator in HCC Progression: Signaling, EMT, Immune Microenvironment, and Novel Therapeutic Perspectives 71
Proteomic study of differential protein expression in stable and unstable human atherosclerotic plaque 70
Structural analysis of plasma glycosaminoglycans in patients undergoing carotid endarterectomy 69
Human serum albumin sulfhydryl groups oxidation in plasma and atherosclerotic plaque extracts 68
Current challenges to underpinning the genetic basis for cholangiocarcinoma 68
eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma 67
Oncogenic potential of N-terminal deletion and S45Y mutant β-catenin in promoting hepatocellular carcinoma development in mice 66
Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis. 64
Quantification of liver proton-density fat fraction in 7.1T preclinical MR systems: Impact of the fitting technique 60
Overexpression of SMAD7 activates the YAP/NOTCH cascade and promotes liver carcinogenesis in mice and humans 59
TAZ is indispensable for c-MYC-induced hepatocarcinogenesis 57
Totale 11.461
Categoria #
all - tutte 47.902
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.902


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022479 37 3 2 4 13 10 21 28 45 24 81 211
2022/20231.114 116 115 48 178 106 167 0 113 189 7 40 35
2023/2024299 52 18 5 13 83 37 2 14 0 5 29 41
2024/20253.002 26 28 175 73 152 87 208 484 1.094 450 144 81
2025/20265.153 253 1.157 1.059 728 454 263 566 144 189 213 90 37
2026/202756 56 0 0 0 0 0 0 0 0 0 0 0
Totale 11.620